© 2017 by Labreakthru. Proudly created with Wix.com

Toronto, Ontario, CA 

Research

From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.

Endocr Relat Cancer. 2017 Apr;24(4):C5-C8

Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A,...

 

Pituitary acromegaly: not one disease.(link is external)

Endocr Relat Cancer. 2017 Jan 25;:

Asa SL, Kucharczyk W, Ezzat S

Pituitary Adenomas Presenting as Sinonasal or Nasopharyngeal Masses: A Case Series Illustrating Potential Diagnostic Pitfalls.(link is external)

Am J Surg Pathol. 2016 Dec 22;:

Hyrcza MD, Ezzat S, Mete O, Asa SL

 

FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.(link is external)

Oncotarget. 2016 Dec 09;:

Ezzat S, Wang R, Pintilie M, Asa SL

 

Ikaros and its interacting partner CtBP target the metalloprotease ADAMTS10 to modulate pituitary cell function.(link is external)

Mol Cell Endocrinol. 2016 Nov 1;439:126-132

Shen Z, Asa SL, Ezzat S

 

Gonadotrope Tumors.(link is external)

Prog Mol Biol Transl Sci. 2016;143:187-210

Asa SL, Ezzat S

 

A detailed spatial analysis on contrasting cancer incidence patterns in thyroid and lung cancer in Toronto women.(link is external)

BMC Public Health. 2016;16:950

Brown P, Jiang H, Ezzat S, Sawka AM

 

Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus.(link is external)

Cancer Treat Rev. 2016 Jun;47:32-45

Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R, Mete O, Pasieka J, Rivera J, Wong R, Segelov E, Rayson D

 

Concerns of low-risk thyroid cancer survivors.(link is external)

Acta Oncol. 2016 May 13;:1-2

Sawka AM, Tsang RW, Brierley JD, Rotstein L, Segal P, Ezzat S, Goldstein DP

 

Thyroid Cancer Incidence and Endocrinologist Access: A Regional Data Analysis from Ontario, Canada.(link is external)

Endocr Pract. 2016 May;22(5):642-3

Sawka AM, Ezzat S, Brown PE

 

Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft.(link is external)

Endocr Pathol. 2016 Apr 11;

Yang Z, Zhang L, Serra S, Law C, Wei A, Stockley TL, Ezzat S, Asa SL

 

NG2 targets tumorigenic Rb inactivation in Pit1-lineage pituitary cells.(link is external)

Endocr Relat Cancer. 2016 Apr 5;

Tateno T, Nakano-Tateno T, Ezzat S, Asa SL

 

High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor.(link is external)

Oncotarget. 2016 Mar 3;

Zhang L, Yang Z, Granieri L, Pasculescu A, Datti A, Asa SL, Xu Z, Ezzat S

 

PANCREATIC INCIDENTALOMAS: IS IT NET OR NOT.(link is external)

Endocr Pract. 2016 Feb 26;

Ezzat S

 

Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.(link is external)

Mod Pathol. 2016 Jan 8;

Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, Ezzat S, Asa SL

 

Unmet Information Needs of Low Risk Thyroid Cancer Survivors.(link is external)

Thyroid. 2015 Dec 16;

Sawka AM, Brierley J, Tsang RW, Rotstein L, Ezzat S, Goldstein DP

 

Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial.(link is external)

Cancer. 2015 Jul 20;

Sawka AM, Straus S, Rodin G, Heus L, Brierley JD, Tsang RW, Rotstein L, Ezzat S, Segal P, Gafni A, Thorpe KE, Goldstein DP

 

Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.(link is external)

Turk Patoloji Derg. 2015;31 Suppl 1:4-17

Gomez-Hernandez K, Ezzat S, Asa SL, Mete Ö

 

Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension.(link is external)

Trials. 2015;16:302

Sawka AM, Straus S, Rodin G, Thorpe KE, Ezzat S, Gafni A, Goldstein DP

 

Lessons learned from thyroglobulin concentrations after total thyroidectomy and radioactive iodine ablation for differentiated thyroid cancer.(link is external)

Clin Biochem. 2015 Jul 8;

Gomez-Hernandez K, Ezzat S

Dr. Sylvia Asa

SERRA S, ZHENG L, HASSAN M, PHAN AT, WOODHOUSE L, YAO JC, EZZAT S, ASA SL: The FGFR4-G388R Single Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy.  Cancer Res 2012;72(22); 1–9. 

EZZAT S, ZHENG L, FLOREZ JC, STEFAN N, MAYR T, HLIANG MM, JABLONSKI K, HARDEN M, STANČÁKOVÁ A, LAAKSO M, HARING H-U, ULLRICH A, ASA SL: The Cancer-Associated FGFR4-G388R Polymorphism  Enhances Pancreatic Insulin Secretion and Modifies the Risk of Diabetes.  Cell Metabolism, 2013;17(6):929-40.

METE O, LOPES MB, ASA SL: Spindle Cell Oncocytomas and Granular Cell Tumors of the Pituitary are Variants of Pituicytoma. Am J Surg Pathol 2013;37(11):1694-9.

CASSOL CA, WINER D, LIU W, GUO M, EZZAT S, ASA SL: Tyrosine kinase receptors as molecular targets in Pheochromocytoma/Paraganglioma.  Modern Pathology, 2014 Aug;27(8):1050-62.

FRANCIS JM, KIEZUN A, RAMOS AH, SERRA S, PEDAMALLU CS,  QIAN ZR, BANCK MS, KANWAR R, KULKARNI AA, KARPATHAKIS A, MANZO V, CONTRACTOR T, PHILIPS J, NICKERSON E, PHO N , HOOSHMAND SM, BRAIS LK, LAWRENCE M, PUGH T, MCKENNA A, SIVACHENKO A, CIBULSKIS C, CARTER SL, OJESINA AI, FREEMAN S, JONES RT, VOET D, SAKSENA G, AUCLAIR D, ONOFRIO R, SHEFLER E, SOUGNEZ C, GRIMSBY J, GREEN L, LENNON N, MEYER T, CAPLIN M, CHUNG DC, BEUTLER AS, OGINO S, HIRLWELL C, SHIVDASANI R, ASA SL, HARRIS CR, GETZ G, KULKE M, MEYERSON M:.Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nature Genetics, 2013 Dec;45(12):1483-6.

 

METE O, TISCHLER AS, DE KRIJGER R, MCNICOL AM, EISENHOFER G, PACAK K, EZZAT S, ASA SL: Protocol for the Examination of Specimens from Patients with Pheochromocytomas and Extra-adrenal Paragangliomas.  Arch Pathol Lab Med 2014;138:182-188.

ASA SL, EZZAT S: Genomic Approaches to Problems in Pituitary Neoplasia, Endocrine Pathology 2014;25:209–213

CHEUNG CC, TORLAKOVIC EE, CHOW H, SNOVER D, ASA SL: Modeling complexity in Pathologist Workload Measurement: The Automatable Activities-Based Approach to Complexity Unit Scoring (AABACUS).  Modern Pathology, 2014; 28(3):324-39. doi: 10.1038/modpathol.2014.123.

CANCER GENOME ATLAS RESEARCH NETWORK: Integrated genomic characterization of papillary thyroid carcinoma.  Cell 2014;159, 676–690.

PAPP S, ASA SL. When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis. Head Neck Pathol 2015 9(1):16-23.

WELLS SA JR, ASA SL, DRALLE H, ELISEI R, EVANS DB, GAGEL RF, LEE NY, MACHENS A, MOLEY JF, PACINI F, RAUE F, FRANK-RAUE K, ROBINSON B, ROSENTHAL MS, SANTORO M, SCHLUMBERGER M, SHAH MH MD, WAGUESPACK SG. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid 2015, 25(6):567-610.

 

KARPATHAKIS A, DIBRA H, PIPINIKAS C, FEBER A, MORRIS T, FRANCIS J, OUKRIF D, MANDAIR D, PERICLEOUS M, MOHMADUVESH M, SERRA S, OGUNBIYI O, NOVELLI M, LUONG T, ASA SL, KULKE M, TOUMPANAKIS C, MEYER T, CAPLIN M, MEYERSON M, BECK S, THIRLWELL C: Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumour.  Clinical Cancer Research, 2016;22(1):250-8.

METE O, GOMEZ-HERNANDEZ K, KUCHARCZYK W, RIDOUT R, ZADEH G, GENTILI F, EZZAT S, ASA SL: Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.  Modern Pathology 2016;29(2):131-42.

ASA SL, EZZAT S: Aggressive pituitary tumors or localized pituitary carcinomas: Defining pituitary tumors. Expert reviews in Endocrinology and Metabolism 2016 11:2, 149-162, DOI: 10.1586/17446651.2016.1153422.    

Dr. Shereen Ezzat

"In addition to their clinical/laboratory practice helping patients like ourselves day in and day out, they have carried out important research that has altered the clinical care of patients."

Our laboratory focuses on investigating the mechanisms underlying tumour development and progression in endocrine tissues. Studies aim to identify genetic and epigenetic changes that characterize these various cancers. Mouse models of these disorders are developed and used to verify the roles of these alterations that are found in human tumours. Once characterized, tests to identify these tumourigenic factors are developed for diagnostic, prognostic and predictive application. The underlying alterations represent targets for the design of novel therapies that can be tested in our mouse models before transition to human trials.